Notice Encouraging Individual Mentored Career Development K08 and K23 Applications Utilizing the National Drug Abuse Treatment Clinical Trials Network (CTN) Resources

Notice Number: NOT-DA-18-001

Key Dates
Release Date: January 17, 2018

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Drug Abuse Treatment Clinical Trials Network (CTN) is a multi-site research program that examines the efficacy of behavioral, pharmacological, and integrated substance use disorder (SUD) treatment interventions, managed through NIDA's Center for Clinical Trials Network (CCTN). The CTN provides a rich platform of scientific and clinical expertise focused on bridging the gap between the development of novel SUD treatment modalities and effective clinical delivery of these interventions to a variety of patient populations in real world settings, making this an ideal environment for qualified clinicians to further develop their independent research careers.

Prospective NIDA K08 and K23 applicants are encouraged to consider incorporating CTN expertise and resources into their proposed research and career development plans. Candidates for these awards must have a clinical doctoral degree. Such degrees include, but are not limited to PhD, MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with other doctoral degrees in clinical disciplines such as nursing, clinical genetics, or rehabilitation are also eligible. Clinicians specializing in internal, family, and/or emergency medicine; infectious disease/HIV; medical genetics; psychiatry; addiction medicine; and bioinformatics are underrepresented in substance use disorder research and are encouraged to apply.

Applicants who choose to develop their research plans utilizing CTN resources must select a primary mentor who is a current CTN Investigator with an MD, PhD, DO, DDS/DMD degree or a nurse with a research doctoral degree.  If the primary mentor is a PhD, then a secondary MD mentor with appropriate scientific expertise as required by the individual career development plan must be selected.  Additional secondary mentors from CTN as well as outside of CTN are allowed as needed and encouraged.

All other individual and institutional eligibility criteria must be met as described in the Parent Funding Opportunity Announcements (FOAs) (see below). Candidates are also encouraged to review the information regarding Clinical Trial Requirements for Grants and Contracts prior to applying. Candidates who apply for funding consideration described in this notice should include the notice serial number in their abstracts (NOT-DA-18-001).

Interested applicants should contact the NIDA Program Official identified below to ensure that they are selecting the appropriate activity (K08 vs. K23) and are applying to the correct FOA (CT Required vs. No CT Allowed) for their career development needs.

Parent FOAs:
Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required) (PA-18-372)
Mentored Clinical Scientist Research Career Development Award (Parent K08 - No Independent Clinical Trials) (PA-18-373)
Mentored Patient-Oriented Research Career Development Award (Parent K23 - Independent Clinical Trial Required) (PA-18-374)
Mentored Patient-Oriented Research Career Development Award (Parent K23 - Independent Clinical Trials Not Allowed) (PA-18-375)

Inquiries

Please direct all inquiries to:

Quandra Blackeney
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-2516
Email: qs3y@nih.gov